Personalis Secures Medicare Coverage, Volume Surges Amidst Revenue Decline
Event summary
- Personalis reported a 14.5% revenue decrease YoY, from $84.6 million to $69.6 million for the full year 2025.
- Clinical test volume increased nearly 400% YoY, reaching 16,233 tests in 2025, and 41% sequentially in Q4 2025.
- The company secured Medicare coverage for breast cancer recurrence surveillance in Q4 2025 and lung cancer in Q1 2026.
- Personalis ended 2025 with $240 million in cash, funded in part by $109 million from an ATM offering at an average price of $8.43 per share.
The big picture
Personalis is attempting to capitalize on the growing demand for advanced genomic testing in oncology, particularly in the area of minimal residual disease (MRD) detection. The Medicare coverage approvals represent a significant opportunity, but the company's revenue decline and reliance on an ATM offering suggest challenges in balancing growth with profitability. The company’s strategy of prioritizing volume adoption ahead of full reimbursement coverage is a high-risk, high-reward approach that could either establish market leadership or exacerbate financial pressures.
What we're watching
- Reimbursement Impact
- The actual uptake of Personalis’ services following Medicare coverage approval will be critical, and the timing of revenue recognition remains uncertain given the stated gross margin strategy.
- Volume Sustainability
- Whether Personalis can maintain the accelerated clinical test volume growth rate achieved in 2025, particularly as reimbursement matures, warrants close monitoring.
- Cash Burn
- The company’s projected $100 million cash usage in 2026, driven by commercial investments, will test the resilience of its balance sheet and necessitate disciplined spending.
Related topics